SubHero Banner

Veklury® (remdesivir) – Revised emergency use authorization

On January 21, 2022, the FDA revised the emergency use authorization (EUA) for Gilead’s Veklury (remdesivir), for the treatment of pediatric patients weighing 3.5 kilograms to less than 40 kilograms or pediatric patients less than 12 years of age weighing at least 3.5 kilograms, with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are not hospitalized and have mild-to-moderate coronavirus disease 2019 (COVID-19), and are at high risk for progression to severe COVID-19, including hospitalization of death.

Download PDF